Lv525
1220 积分 2024-05-01 加入
Meeting the Unmet Needs in Rare Cancer
16天前
已完结
Association of metformin use and cancer incidence: a systematic review and meta-analysis
25天前
已完结
Therapy with oncolytic viruses: progress and challenges
1个月前
已完结
Immunotherapy for hepatocellular carcinoma
1个月前
已完结
Management of Hepatocellular Carcinoma
1个月前
已完结
Exploring tumor organoids for cancer treatment
1个月前
已完结
Clinical implications of T cell exhaustion for cancer immunotherapy
2个月前
已完结
Antibody–drug conjugates come of age in oncology
2个月前
已完结
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
2个月前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
